Iroko Pharmaceuticals failed to launch a $145 million IPO earlier in the year, but it has managed to win regulatory approval for a lower-dose, nonsteroidal anti-inflammatory drug--Zorvolex--which promises to ease mild to moderate levels of pain with a lower risk to patients. Higher doses of NSAIDs have been linked to strokes, gastrointestinal ulcers and acute renal failures. Story